# Translational Oncology Research Program (Project-005)

> **NIH NIH P30** · STANFORD UNIVERSITY · 2020 · $43,892

## Abstract

PROJECT SUMMARY – TOPS 
The overarching goal of the Translational Oncology Program at Stanford (TOPS) is to foster collaboration 
across scientific and clinical disciplines in order to gain deeper insights into the underlying causes of cancer 
and to develop more effective diagnostic, prognostic and therapeutic approaches to cancer. The TOPS 
Program was newly created in 2013 to meet the translational goals of the SCI. The program brings together 
translational and clinical researchers, chemists, biologists and biostatisticians who have a focus on projects 
that will have substantial clinical impact on solid tumors. The program is based on the activities of a number 
of working groups including the solid tumor Clinical Research Groups (CRGs) and the Developmental 
Therapeutics (Phase I) Working Group. Program members meet monthly to discuss topics of broad general 
interest to translational researchers. The new Jill and John Freidenrich Center for Translational Research 
(FCTR) provides a venue that brings together interdisciplinary teams of investigators and research staff 
whose interests are centered around specific cancer types. The building provides collaborative meeting 
spaces and serves as a single convenient location for the disease-specific interdisciplinary research teams. 
All TOPS meetings and working groups encourage the participation of graduate students and fellows to 
form new interdisciplinary interactions. 
Co-led by Mark Pegram, MD and George Sledge, MD, the 42 members of the TOPS Program represent 
16 departments and three schools within the University, of whom 13 have been recruited to the Stanford 
faculty since the last review. The research activities of the 42 investigators are supported by 27 peer- 
reviewed, investigator-initiated grants and include a NCI U10 grant. Peer-reviewed funding consists of 
$8.1M in total annual costs of which $4.2M is from the NCI. Other NIH support amounts to $3.0M, and other 
peer-reviewed support to $0.9 million. Since 2009, program members have published over 570 manuscripts 
of which 12% are intra- and 34% are inter-programmatic. The SCI will continue to be invaluable to the 
program by fostering innovative projects and assisting with the translation of research findings into the clinic 
for the benefit of cancer patients.

## Key facts

- **NIH application ID:** 9936163
- **Project number:** 5P30CA124435-13
- **Recipient organization:** STANFORD UNIVERSITY
- **Principal Investigator:** Mark Daniel Pegram
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $43,892
- **Award type:** 5
- **Project period:** — → 2022-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9936163

## Citation

> US National Institutes of Health, RePORTER application 9936163, Translational Oncology Research Program (Project-005) (5P30CA124435-13). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/9936163. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*